New obesity drug tested in chinese adults for first time
NCT ID NCT06352892
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a single injection of a new drug called AMG 133 (Maridebart Cafraglutide) in 20 overweight or obese Chinese adults. The main goal was to see how the drug moves through the body and to check for any safety issues. This is a first step to see if the drug might be a future treatment for obesity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Maridebart Cafraglutide (AMG 133)
What this could lead to
If successful, this could support further development of AMG 133 as a weight management option for people with obesity.
What could go wrong
This is a very early Phase 1 study with only 20 participants. It is designed to check safety and drug levels, not to prove weight loss. Many early-stage drugs do not advance to later trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Queen Mary Hospital
Hong Kong, 000, Hong Kong